Bard's Corrected and Revised Objections and Counter-Designations to AngioDynamics' 9/13/2022 Affirmative Designations						
		Angio Dynamics'		9		
Name of Deponent	Date of Testimony	Affirmative	Bard's Objections to Affirmative	Bard's Counter-Designations	Court's Ruling	
•		Designations	Designations		°	
Ingold, Jack	May 17, 2022	198:1 – 198:13				
Ingold, Jack	May 17, 2022	354:20-355:13		355:14-21		
Ingold, Jack	May 17, 2022	357:17-357:22	Vague, lacks foundation		Overruled	
Ingold, Jack	May 17, 2022	358:2-358:3				
Ingold, Jack	May 17, 2022	358:5-358:9				
Ingold, Jack	May 17, 2022	358:12-358:17				
Ingold, Jack	May 17, 2022	358:19-359:9				
Ingold, Jack	May 17, 2022	359:10-359:15	Cumulative; asked and answered.		Overruled	
Ingold, Jack	May 17, 2022	359:18-360:3	Cumulative; asked and answered.		Overruled	
Ingold, Jack	May 17, 2022	360:5-360:20	Cumulative		Sustained	
Ingold, Jack	May 17, 2022	360:21-361:3	Cumulative		Sustained	
Ingold, Jack	May 17, 2022	361:6-361:9	Cumulative		Sustained	
Ingold, Jack	May 17, 2022	361:11-361:15	Leading; misleading the jury		Sustained	
Ingold, Jack	May 17, 2022	361:17-361:20				
Ingold, Jack	May 17, 2022	361:22-362:5				
					Sustained	
		362:7-362:7	Leading; misleading the jury		(remove question	
Ingold, Jack	May 17, 2022				above as well)	
		362:9-363:19	Objection to 362:9-20 - Leading; misleading the		Contained	
Ingold, Jack	May 17, 2022	302:9-303:19	jury		Sustained	
Ingold, Jack	May 17, 2022	363:20-364:19				
Ingold, Jack	May 17, 2022	364:20-364:21				
Ingold, Jack	May 17, 2022	365:2-365:16				
Ingold, Jack	May 17, 2022	365:18-365:21	Foundation		Overruled	
Ingold, Jack	May 17, 2022	366:2-366:2	Foundation		Overruled	
Ingold, Jack	May 17, 2022	366:4-366:6	Foundation		Overruled	
Ingold, Jack	May 17, 2022	366:10-366:15	Foundation		Overruled	
Ingold, Jack	May 17, 2022	366:20-367:18				
Ingold, Jack	May 17, 2022	367:19-368:11	Foundation; hearsay		Sustained	
Ingold, Jack	May 17, 2022	368:12-368:21	Foundation; hearsay		Sustained	
Ingold, Jack	May 17, 2022	369:2-369:4				
Ingold, Jack	May 17, 2022	369:6-369:9	Foundation; hearsay		Sustained	
Kokotis, Kathy	January 10, 2020	4:19 -4:21				
Kokotis, Kathy	January 10, 2020	12:3 -12:23				

Name of Deponent	Date of Testimony	AngioDynamics' Affirmative Designations	Bard's Objections to Affirmative Designations	Bard's Counter-Designations	Court's Ruling
Kokotis, Kathy	January 10, 2020	45:15 -46:11	Bard Obj. to P-217, 401/402 - Relevance (AngioDynamics argues relevant to product differentiation and motive; no evidence that any product differentiation based on coatings were relevant to Bard's motivation for its TLS policy) 801/802 - Hearsay 611 (foundation)		Overruled
Kokotis, Kathy	January 10, 2020	47:22 -47:25	policy), 801/802 - Hearsay, 611 (foundation) Bard Obj. to P-217, Bard Obj. to Angio Affirm. 47:22 -47:25, 48:2 -48:7, 48:10 -48:11, 401/402 Relevance (AngioDynamics argues relevant to product differentiation and motive; no evidence that any product differentiation based on coatings were relevant to Bard's motivation for its TLS policy), 611 (lacks foundation), 801/802 (hearsay)	189:14-189:25, 190:3-190:16, 190:18- 190:25, 191:2-191:6, 191:8-191:10	Sustained (hearsay)
Kokotis, Kathy	January 10, 2020	48:2 -48:7	(hearsay) Bard Obj. to P-217, Bard Obj. to Angio Affirm. 47:22 -47:25, 48:2 -48:7, 48:10 -48:11, 401/402 Relevance (AngioDynamics argues relevant to product differentiation and motive; no evidence that any product differentiation based on coatings were relevant to Bard's motivation for its TLS policy), 611 (lacks foundation), 801/802 (hearsay)	189:14-189:25, 190:3-190:16, 190:18- 190:25, 191:2-191:6, 191:8-191:10	Overruled
Kokotis, Kathy	January 10, 2020	48:10 -48:11	Bard Obj. to P-217, Bard Obj. to Angio Affirm. 47:22 -47:25, 48:2 -48:7, 48:10 -48:11, 401/402 Relevance (AngioDynamics argues relevant to product differentiation and motive; no evidence that any product differentiation based on coatings were relevant to Bard's motivation for its TLS policy), 611 (lacks foundation), 801/802 (hearsay)		Overruled
Kokotis, Kathy	January 10, 2020	49:3 -49:7	Bard Obj. to P-217, Bard Obj. to Angio Affirm 49:3-7 - 401/402 - Relevance (AngioDynamics argues relevant to product differentiation and motive; no evidence that any product differentiation based on coatings were relevant to Bard's motivation for its TLS policy), 403 (prejudice, confusion)	49:23-49:24, 50:2-50:11	Sustained

Name of Deponent	Date of Testimony	AngioDynamics' Affirmative Designations	Bard's Objections to Affirmative Designations	Bard's Counter-Designations	Court's Ruling
Kokotis, Kathy	January 10, 2020	50:12 -50:25	Bard Obj. to P-217, Bard Obj. to Angio Affirm. 50:12-51:2, 401/402 - Relevance (AngioDynamics argues relevant to product differentiation and motive; no evidence that any product differentiation based on coatings were relevant to Bard's motivation for its TLS policy), 403 (prejudice, confusion), 611 (lacks foundation)		Overruled
Kokotis, Kathy	January 10, 2020	51:2 -51:15	foundation) Bard Obj. to P-217, Bard Obj. to Angio Affirm. 51:3-15, 401/402 - Relevance (AngioDynamics argues relevant to product differentiation and motive; no evidence that any product differentiation based on coatings were relevant to Bard's motivation for its TLS policy), 403 (prejudice, confusion) Bard Obj. to P-217, Bard Obj. to Angio Affirm.		Overruled
Kokotis, Kathy	January 10, 2020	53:8 -53:25	53:8 -53:25, 54:2 -54:13, 401/402 - Relevance (AngioDynamics argues relevant to product differentiation and motive; no evidence that any product differentiation based on coatings were relevant to Bard's motivation for its TLS	54:14-54:15, 54:17-54:17	Overruled
Kokotis, Kathy	January 10, 2020	54:2 -54:13	policy), 403 (preiudice, confusion) Bard Obj. to P-217, Bard Obj. to Angio Affirm. 53:8 -53:25, 54:2 -54:13, 401/402 - Relevance (AngioDynamics argues relevant to product differentiation and motive; no evidence that any product differentiation based on coatings were relevant to Bard's motivation for its TLS policy), 403 (preiudice, confusion) Bard Obj. to P-217, Bard Obj. to Angio Affirm.		Overruled
Kokotis, Kathy	January 10, 2020	54:18 -54:25	Bard Obj. to P-217, Bard Obj. to Angio Affirm. 54:18 -54:25, 55:2 -55:13, 401/402 - Relevance (AngioDynamics argues relevant to product differentiation and motive; no evidence that any product differentiation based on coatings were relevant to Bard's motivation for its TLS policy), 403 (prejudice, confusion), 611 (lacks foundation)		Overruled

Name of Deponent	Date of Testimony	AngioDynamics' Affirmative Designations	Bard's Objections to Affirmative Designations	Bard's Counter-Designations	Court's Ruling
Kokotis, Kathy	January 10, 2020	55:2 -55:13	Bard Obj. to P-217, Bard Obj. to Angio Affirm. 54:18 -54:25, 55:2 -55:13, 401/402 - Relevance (AngioDynamics argues relevant to product differentiation and motive; no evidence that any product differentiation based on coatings were relevant to Bard's motivation for its TLS policy), 403 (prejudice, confusion), 611 (lacks foundation)		Overruled
Kokotis, Kathy	January 10, 2020	56:16 -56:25	Bard Obj. to P-117, 401/402 - Relevance, 403 - Confusing/Prejudicial		Overruled
Kokotis, Kathy	January 10, 2020	57:2 -57:25	Bard Obj. to P-117, 401/402 - Relevance, 403 - Confusing/Prejudicial		Overruled
Kokotis, Kathy	January 10, 2020	58:2 -58:11	Bard Obj. to P-117, Bard Obj. to Angio Affirm. 58:2-11, 401/402 - Relevance, 403 (prejudice, confusion), 611 (vague)		Sustained
Kokotis, Kathy	January 10, 2020	58:12 -58:25	Bard Obj. to P-117, Bard Obj. to Angio Affirm. 58:12 -58:25, 59:2 -59:4, 401/402 - Relevance, 403 (prejudice, confusion), 602 (speculation), 611 (compound, vague)		Sustained
Kokotis, Kathy	January 10, 2020	59:2 -59:4	Bard Obj. to P-117, Bard Obj. to Angio Affirm. 58:12 -58:25, 59:2 -59:4, 401/402 - Relevance, 403 (prejudice, confusion), 602 (speculation), 611 (compound, vague)		Sustained
Kokotis, Kathy	January 10, 2020	59:5 -59:10	Bard Obj. to P-117, Bard Obj. to Angio Affirm. 59:5-10, 401/402 - Relevance, 403 (prejudice, confusion), 611 (vague, lacks foundation)		Sustained
Kokotis, Kathy	January 10, 2020	59:11 -59:12	Bard Obj. to P-117, Bard Obj. to Angio Affirm. 59:11-59:12, 59:14-59:20, 59:24-59:25, 60:2-60:8, 60:23-60:25, 61:3-61:17, 401/402-Relevance, 403 (prejudice), 611 (vague, lacks foundation)		Sustained
Kokotis, Kathy	January 10, 2020	59:14 -59:20	Bard Obj. to P-117, Bard Obj. to Angio Affirm. 59:11-59:12, 59:14-59:20, 59:24-59:25, 60:2-60:8, 60:23-60:25, 61:3-61:17, 401/402-Relevance, 403 (prejudice), 611 (vague, lacks foundation)		Sustained

Name of Deponent	Date of Testimony	AngioDynamics' Affirmative Designations	Bard's Objections to Affirmative Designations	Bard's Counter-Designations	Court's Ruling
			Bard Obj. to P-117, Bard Obj. to Angio Affirm.		
			59:11-59:12, 59:14 -59:20, 59:24 -59:25, 60:2 -		
		59:24 -59:25	60:8, 60:23 -60:25, 61:3 -61:17, 401/402 -		Sustained
			Relevance, 403 (prejudice), 611 (vague, lacks		
Kokotis, Kathy	January 10, 2020		foundation)		
			Bard Obj. to P-117, Bard Obj. to Angio Affirm.		
			59:11-59:12, 59:14 -59:20, 59:24 -59:25, 60:2 -		
		60:2 -60:8	60:8, 60:23 -60:25, 61:3 -61:17, 401/402 -		Sustained
** 1 . ** ** 1	10.000		Relevance, 403 (prejudice), 611 (vague, lacks		
Kokotis, Kathy	January 10, 2020		foundation)		
			Bard Obj. to P-117, Bard Obj. to Angio Affirm.		
		60.00 60.05	59:11-59:12, 59:14 -59:20, 59:24 -59:25, 60:2 -		G 1
		60:23 -60:25	60:8, 60:23 -60:25, 61:3 -61:17, 401/402 -		Sustained
TZ 1 4' TZ 41	10, 2020		Relevance, 403 (prejudice), 611 (vague, lacks		
Kokotis, Kathy	January 10, 2020		foundation) Bard Obj. to P-117, Bard Obj. to Angio Affirm.		
			59:11-59:12, 59:14 -59:20, 59:24 -59:25, 60:2 -		
		61:3 -61:17	60:8, 60:23 -60:25, 61:3 -61:17, 401/402 -		Sustained
		01:3 -01:17	Relevance, 403 (prejudice), 611 (vague, lacks		Sustained
Kokotis, Kathy	January 10, 2020		7 4 5 // (5 /		
Kokotis, Katily	January 10, 2020		foundation) Bard Obj. to P-117, Bard Obj. to Angio Affirm.		
		61:18 -62:5	61:18-62:5, 401/402 (relevance), 403		Sustained
Kokotis, Kathy	January 10, 2020	01.16 -02.3	(prejudice, confusion)		Sustained
Rokotis, Rutily	Junuary 10, 2020		Bard Obj. to P-117, Bard Obj. to Angio Affirm.		
		62:6 -62:17	62:6-17, 401/402 (relevance), 403 (prejudice,		Overruled
Kokotis, Kathy	January 10, 2020	02.0 02.17	confusion)		Overranea
Tronous, Trainj	tuituut j 10, 2020		Bard Obj. to P-117, Bard Obj. to Angio Affirm.		
			63:6-63:14, 401/402 (relevance), 403		
		63:6 -63:14	(prejudice, confusion), 602 (misstates prior		Sustained
Kokotis, Kathy	January 10, 2020		testimony)		
,	,		Bard Obj. to P-117, Bard Obj. to Angio Affirm.		
		63:15 -63:25	63:15 -63:25, 64:2 -64:3, 401/402 (relevance),		Sustained
Kokotis, Kathy	January 10, 2020		403 (prejudice, confusion)		
-			Bard Obj. to P-117, Bard Obj. to Angio Affirm.		
		64:2 -64:3	63:15 -63:25, 64:2 -64:3, 401/402 (relevance),		Sustained
Kokotis, Kathy	January 10, 2020		403 (prejudice, confusion)		

Name of Deponent	Date of Testimony	AngioDynamics' Affirmative Designations	Bard's Objections to Affirmative Designations	Bard's Counter-Designations	Court's Ruling
			Bard Obj. to P-117, Bard Obj. to Angio Affirm.		
		65:3 -65:15	63:15 -63:25, 64:2 -64:3, 401/402 (relevance),		Overruled
Kokotis, Kathy	January 10, 2020		403 (prejudice, confusion)		
			Bard Obj. to P-117, Bard Obj. to Angio Affirm.		
		72:9 -72:12	63:15 -63:25, 64:2 -64:3, 401/402 (relevance),		Overruled
Kokotis, Kathy	January 10, 2020		403 (prejudice, confusion), 602 (speculation)		
			Bard Obj. to Angio Affirm. 72:13-73:10, 72:23 -	•	
		72:13 -72:21	73:3, 403 (prejudice, confusion), 602		Sustained
Kokotis, Kathy	January 10, 2020		(speculation)		
			Bard Obj. to Angio Affirm. 72:13-73:10, 72:23 -	•	
		72:23 -73:3	73:3, 403 (prejudice, confusion), 602		Sustained
Kokotis, Kathy	January 10, 2020		(speculation)		
	•		Bard Obj. to Angio Affirm. 150:13-150:16,		
		1.50.10.150.16	150:18-150:25, 151:2-151:17, 401/402		
		150:13 -150:16	(relevance), 602 (speculation, assumes facts not		Overruled
Kokotis, Kathy	January 10, 2020		in evidence), 611 (lacks foundation)		
,	<i>j</i> , , , , , , , , , , , , , , , , , , ,		Bard Obj. to Angio Affirm. 150:13-150:16,		
			150:18-150:25, 151:2-151:17, 401/402		
		150:18 -150:25	(relevance), 602 (speculation, assumes facts not		Overruled
Kokotis, Kathy	January 10, 2020		in evidence), 611 (lacks foundation)	150:4-150:12	
			Bard Obj. to Angio Affirm. 150:13-150:16,		
			150:18-150:25, 151:2-151:17, 401/402		
		151:2 -151:17	(relevance), 602 (speculation, assumes facts not		Overruled
Kokotis, Kathy	January 10, 2020		in evidence), 611 (lacks foundation)	150:4-150:12	
Patil, Nitin	April 19, 2022	5:3-5:5	in evidence), or i (lacks foundation)	130.1 130.12	
Patil, Nitin	April 19, 2022	25:2-25:12			
Patil, Nitin	April 19, 2022	52:12-52:14			
Patil, Nitin	April 19, 2022	52:16-52:25			
Patil, Nitin	April 19, 2022	53:2-53:14			
Patil, Nitin	April 19, 2022	60:15-60:19	misstates testimony	59:25-60:14	Overruled
Patil, Nitin	April 19, 2022	60:21-61:2	Inistates testimony	37.23 00.11	Overruled
1 4111, 1 111111	1 pm 17, 2022	00.21 01.2			Overruled, but
					incomplete
		ril 19, 2022 101:11-102:14			designation
Patil, Nitin	April 19, 2022				(missing question
					or should start on
			misstates testimony, assumes facts	101:7-9, 102:15-19, 102:22	
			imporares resumony, assumes facts	101.7-9, 102.13-19, 102.22	line 12)

Name of Deponent	Date of Testimony	AngioDynamics' Affirmative Designations	Bard's Objections to Affirmative Designations	Bard's Counter-Designations	Court's Ruling
Patil, Nitin	April 19, 2022	103:24-104:13			
Patil, Nitin	April 19, 2022	107:16-109:13		109:20-22, 109:24-110:2	
Patil, Nitin	April 19, 2022	122:23-123:10	testimony discusses exhibit not introduced in deposition designations		Sustained
Patil, Nitin	April 19, 2022	125:15-125:21		125:22-25	
Patil, Nitin	April 19, 2022	126:4-126:14			
Patil, Nitin	April 19, 2022	126:18-127:5	misstates document		Overruled
Patil, Nitin	April 19, 2022	127:7-127:7	misstates document		Overruled
Patil, Nitin	April 19, 2022	129:9-129:16			
Patil, Nitin	April 19, 2022	132:17-133:7			
Patil, Nitin	April 19, 2022	133:9-134:9			
Patil, Nitin	April 19, 2022	140:20-140:24	speculation, improper hypothetical		Sustained
Patil, Nitin	April 19, 2022	141:3-141:14	speculation, improper hypothetical		Sustained
Patil, Nitin	April 19, 2022	142:2-142:9			
Patil, Nitin	April 19, 2022	153:15-154:7			
Patil, Nitin	April 19, 2022	156:10-156:14			
Patil, Nitin	April 19, 2022	163:3-163:10	vague, misstates testimony		Overruled
Patil, Nitin	April 19, 2022	167:6-167:16	vague, misstates testimony		Overruled
Patil, Nitin	April 19, 2022	200:22-201:10	vague, misstates testimony		Overruled
Patil, Nitin	April 19, 2022	201:13-201:16			
Patil, Nitin	April 19, 2022	201:18-201:23			
Patil, Nitin	April 19, 2022	202:8-202:15			
Patil, Nitin	April 19, 2022	215:4-215:7			
Patil, Nitin	April 19, 2022	217:17-217:19			
Patil, Nitin	April 19, 2022	220:7-220:10	speculation		Sustained
Patil, Nitin	April 19, 2022	220:13-220:17	speculation		Sustained as to 220:13
Patil, Nitin	April 19, 2022	220:19-220:19	speculation		Overruled
Patil, Nitin	April 19, 2022	223:9-223:13	P-223 - 801/802 - Hearsay (e.g., page 3-4, "Spent about 45 minutes on the phone with Mark on Wednesday"; page 2, "As I recalle there was an 'Allegation' of an air embolism" page 1, "Anectodately, we are told"401/402 - Relevance; 403 - Waste of TIme/Confusion		Overruled
Patil, Nitin	April 19, 2022	228:4-228:12	speculation, misstates document		Sustained as to 228:8-12
Patil, Nitin	April 19, 2022	230:11-231:6			

Name of Deponent	Date of Testimony	AngioDynamics' Affirmative Designations	Bard's Objections to Affirmative Designations	Bard's Counter-Designations	Court's Ruling
Patil, Nitin	April 19, 2022	232:2-232:14	misstates document, misstates testimony		Overruled
Patil, Nitin	April 19, 2022	237:21-237:25	speculation	237:6-20, 238:2-17	Overruled
Patil, Nitin	April 19, 2022	239:6-239:10	speculation		Overruled
Patil, Nitin	April 19, 2022	239:14-239:18			
Patil, Nitin	April 19, 2022	245:25-246:22			
Patil, Nitin	April 19, 2022	255:13-255:17			
Patil, Nitin	April 19, 2022	255:19-255:20			
Patil, Nitin	April 19, 2022	256:15-256:17			
Patil, Nitin	April 19, 2022	258:13-258:20			
Patil, Nitin	April 19, 2022	258:22-258:23			
Patil, Nitin	April 19, 2022	259:5-259:6			
Patil, Nitin	April 19, 2022	259:9-259:25			
Patil, Nitin	April 19, 2022	263:6-263:21	speculation		Overruled
Patil, Nitin	April 19, 2022	269:9-270:11		270:12-271:3	
Patil, Nitin	April 19, 2022	273:11-274:12			
Patil, Nitin	April 19, 2022	277:6-277:9			
Patil, Nitin	April 19, 2022	281:4-281:17	beyond geographic scope ("all over the world")		Sustained
Patil, Nitin	April 19, 2022	288:13-289:16	403 - prejudicial, 401/402 - irrelevant, violates assurance that designations would be "targeted to elements of AngioDynamics' case" (ECF 356)	287:21-288:6, 289:21-290:3	Sustained

Dated: September 22, 2022

Brenda K. Sannes

Chief U.S. District Judge